Genentech rethinks Avastin limits

Well, on second thought...maybe Genentech won't restrict supplies of Avastin. This turnabout announcement comes after the company met with eye specialists who were hopping mad that patients might be forced to buy Lucentis at $2,000 per dose versus Avastin at $40.

The company says it will need the FDA's OK to continue selling to compounding pharmacists who split Avastin vials into small doses for eye use. But it will postpone the distribution restrictions until January to give ophthalmologists time to find alternate sources.

- read the report from the San Francisco Chronicle

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.